Fig. 4: Effects of KRAS G12C inhibitors on fumarate accumulation and ASS1 levels in KRAS G12C-mutant cell lines. | Cell Death Discovery

Fig. 4: Effects of KRAS G12C inhibitors on fumarate accumulation and ASS1 levels in KRAS G12C-mutant cell lines.

From: Cetuximab co-treatment with KRAS G12C inhibitors fulzerasib and sotorasib in human KRAS G12C non-small cell lung cancer cells

Fig. 4: Effects of KRAS G12C inhibitors on fumarate accumulation and ASS1 levels in KRAS G12C-mutant cell lines.The alternative text for this image may have been generated using AI.

Fumarate accumulation curves at 72 h upon fulzerasib/sotorasib treatment in A H358, B H23 and C H2030 cell line. Bars indicate mean ± SEM of two independent experiments. *p < 0.05. Values shown are means of two independent experiments. D Western blot analysis of ASS1 upon treatment in KRAS G12C-mutant cell lines (H358, H23 and H2030). Loading control Hsp90 corresponds to bands of Fig. 2. The intensity of the bands was first normalized using Hsp90, and then normalized to the basal condition (timepoint 0). Bands were quantified using ImageJ software.

Back to article page